http://www.fda.gov/cder/orange/appendix_a.txt ACTHAR GEL, CORTICOTROPIN H.R.-50, HYDROCHLOROTHIAZIDE HABITROL, NICOTINE (OTC) HALCION, TRIAZOLAM HALDOL SOLUTAB, HALOPERIDOL HALDOL, HALOPERIDOL HALDOL, HALOPERIDOL DECANOATE HALDOL, HALOPERIDOL LACTATE HALDRONE, PARAMETHASONE ACETATE HALFAN, HALOFANTRINE HYDROCHLORIDE HALOG, HALCINONIDE HALOG-E, HALCINONIDE HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE HALOPERIDOL INTENSOL,...
Prescription and OTC Drug Product List 11/1999 Prescription and Over-the-Counter Drug Product List - 19th Edition Cumulative Supplement Number 11: November 1999 [ Prescription - OTC ] - ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ALBUTEROL SULFATE BUPROPION HYDROCHLORIDE SOLUTION; INHALATION TABLET; ORAL ALBUTEROL SULFATE - ADD - BUPROPION HCL - ADD - AN MORTON GROVE EQ 0.083% BASE N75394 001 - ADD - AB TEVA 100MG...
FDA Drug Approvals List November 1999 Approvable Original New Drug Applications Original Application #: 020125 Approvable Date: 30-NOV-99 Trade Name: ACCURETIC Dosage Form: TABLET Applicant: PARKE DAVIS PHARMACEUTICAL RESEARCH DIV WARNER LAMBERT CO Active Ingredient(s): QUINAPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE OTC/RX Status: RX Original Abbreviated Application #: 075366 Tentative Approval Date: 02-NOV-99 Trade Name:...
http://www.fda.gov/cder/foi/appletter/1999/40312ltr.pdf ANDA 40- 312 November 19, 1999 Novo Nordisk Pharmaceuticals, IncInnofem O Tablets (Estradiol Tablets, USP), 0.5 mg, 1 mg, and 2 mg...
http://www.fda.gov/cder/foi/appletter/1999/40312ltr.pdf page 1
Financial statement for the first quarter of 2001 Stock Exchange Announcement No 9 / 2001 Page 1 of 9 Novo Nordisk A/ S Novo Alle Telephone: Internet: CVR Number: Corporate Communications 2880 Bagsvaerd +45 4444 8888 www
author: Novo Nordisk A/S
Financial statement for the first quarter of 2001 page 5
author: Novo Nordisk A/S
Novo Nordisk sFinancial statement for the first half of 2001 Stock Exchange Announcement No 12 / 2001 Page 1 of 10 Novo Nordisk A/ S Novo Alle Telephone: Internet: CVR Number: Corporate Communications 2880 Bagsvaerd +45 4444 8888 www
author: Novo Nordisk A/S
Novo Nordisk sFinancial statement for the first half of 2001 page 5
author: Novo Nordisk A/S
Perspective August 2001 - Strong presence at the ADA Novo Nordisk participated with its biggest ever exhibition booth
Perspective May 2001 - Page 3 - New studies target new markets Originally launched as a niche product for a rare type of haemophilia, NovoSeven® is now a candidate to become the world's first general haemostatic agent
Perspective August 2000 - Page 2 Enzyme Business sells enzymes on-line Novo Nordisk Enzyme Business has brought a whole new meaning to the abbreviation EB
http://www.novonordisk.com/old/press/perspective/1998august/uk/4.html Growth factors in a challenging market Cost curbing measures and economic recession are among the challenges facing Novo Nordisk in Japan
http://www.novonordisk.com/old/press/perspective/1998august/uk/3.html Growth factors in a challenging market Cost curbing measures and economic recession are among the challenges facing Novo Nordisk in Japan
